NASDAQ:PROK ProKidney Q3 2026 Earnings Results & Report $1.04 -0.11 (-9.13%) Closing price 04:00 PM EasternExtended Trading$1.10 +0.06 (+5.74%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProKidney missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.17 versus the -$0.1598 consensus estimate, while revenue of $174 thousand topped the $125 thousand estimate by $49.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeAfter Market ClosesConference Call7:00 AM ET ProKidney EPS ResultsActual EPS-$0.17Consensus EPS -$0.1598Beat/MissMissed by -$0.0102One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersProKidney Revenue ResultsActual Revenue$174 thousandExpected Revenue$125 thousandBeat/MissBeat by +$49.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ProKidney Q3 2026 Earnings FAQ Did ProKidney beat earnings estimates for Q3 2026? ProKidney (NASDAQ:PROK) reported earnings of -$0.17 per share for Q3 2026, missing the consensus estimate of -$0.1598. The report was announced on Thursday, November 12, 2026. What was ProKidney's revenue for Q3 2026? ProKidney reported revenue of $174 thousand for Q3 2026, against a consensus estimate of $125 thousand. ProKidney Earnings HeadlinesProKidney Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13 at 9:37 AM | marketscreener.comMProKidney Q3 2026: Wider Loss Signals a High-Stakes Trial SprintNovember 12 at 6:45 PM | 247wallst.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.November 13 at 1:00 AM | Crypto 101 Media (Ad)ProKidney Reports Third Quarter 2026 Financial Results and Business HighlightsNovember 12 at 4:10 PM | globenewswire.comProKidney (PROK) Expected to Post Quarterly Earnings on MondayNovember 8, 2026 | americanbankingnews.comProKidney Corp. enters into $200,000,000 open market sale agreement with Jefferies LLCNovember 3, 2026 | msn.comSee More ProKidney Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email. Email Address About ProKidneyProKidney (NASDAQ:PROK) is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment. ProKidney is based in Winston-Salem, North Carolina. Its activities are centered on research and clinical development of REACT and related cell therapy approaches.View ProKidney ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense OpportunityThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
